Floatz logo

Dexrazoxane

Blasts 10 Percent or More of Bone Marrow Nucleated Cells

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Blasts 10 Percent or More of Bone Marrow Nucleated Cells cohort.

Asset / SponsorPhaseRating
Fludarabine
Sumithira Vasu
Phase 2BB
Gilteritinib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3BB
Cytosin-Arabinosid
Sumithira Vasu
Phase 2BB
Thiotepa
Fred Hutchinson Cancer Center
Phase 2B
Azacitidine
Aptose Biosciences Inc.
Phase 2B

View all 29 →

Same molecule, other indications

Dexrazoxane is also rated in:

diffuse large B-cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
B
Indicative ·
59 / 100
View asset →
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →